The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: An exploratory, hypothesis-generating study

Journal of Pathology

Volumn 237, Issue 2, 2015, Pages 166-178

  Guerini Rocco, Elena ^a,b   Hodi, Zsolt ^c   Piscuoglio, Salvatore ^a   Ng, Charlotte K Y ^a   Rakha, Emad A ^c   Schultheis, Anne M ^a   Marchiò, Caterina ^a,d   Da Cruz Paula, Arnaud ^a   De Filippo, Maria R ^a   Martelotto, Luciano G ^a   De Mattos Arruda, Leticia ^a,e   Edelweiss, Marcia ^a   Jungbluth, Achim A ^a   Fusco, Nicola ^a,b   Norton, Larry ^a   Weigelt, Britta ^a   Ellis, Ian O ^c   Reis Filho, Jorge S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF TURIN   (Italy)

^e VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

Author keywords

breast cancer; immunohistochemistry; massively parallel sequencing; TP53; triple negative

Indexed keywords

BETA CATENIN; BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GENOMIC DNA; INOSITOL POLYPHOSPHATE 4 PHOSPHATASE TYPE 2; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; UVOMORULIN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ACINAR CELL CARCINOMA; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER SIZE; CLINICAL ARTICLE; COPY NUMBER VARIATION; DNA REPAIR; EXON; FOLLOW UP; FRAMESHIFT MUTATION; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDEL MUTATION; MIDDLE AGED; PRIORITY JOURNAL; SOMATIC MUTATION; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; CANCER GRADING; CHEMISTRY; DISEASE COURSE; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; MICRODISSECTION; MUTATION; PATHOLOGY; PHENOTYPE;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, ACINAR CELL; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MICRODISSECTION; MIDDLE AGED; MUTATION; NEOPLASM GRADING; PHENOTYPE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84940891503     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4566     Document Type: Article

References (65)

1. Foschini MP, Krausz T,. Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including 'triple negative carcinomas' of low malignant potential. Semin Diagn Pathol 2010; 27: 77-90.
2. Lakhani SR, Ellis IO, Schnitt SJ, et al,. WHO Classification of Tumours of the Breast (4th edn). IARC Press: Lyon, 2012.
3. Damiani S, Pasquinelli G, Lamovec J, et al,. Acinic cell carcinoma of the breast: an immunohistochemical and ultrastructural study. Virchows Arch 2000; 437: 74-81.
4. Limite G, Di Micco R, Esposito E, et al,. Acinic cell carcinoma of the breast: review of the literature. Int J Surg 2014; 12 (Suppl 1): S35-S39.
5. Roncaroli F, Lamovec J, Zidar A, et al,. Acinic cell-like carcinoma of the breast. Virchows Arch 1996; 429: 69-74.
6. Coyne JD, Dervan PA,. Primary acinic cell carcinoma of the breast. J Clin Pathol 2002; 55: 545-547.
7. Peintinger F, Leibl S, Reitsamer R, et al. Primary acinic cell carcinoma of the breast: a case report with long-term follow-up and review of the literature. Histopathology 2004; 45: 645-648.
8. Huo L, Bell D, Qiu H, et al,. Paneth cell-like eosinophilic cytoplasmic granules in breast carcinoma. Ann Diagn Pathol 2011; 15: 84-92.
9. Pia-Foschini M, Reis-Filho JS, Eusebi V, et al,. Salivary gland-like tumours of the breast: surgical and molecular pathology. J Clin Pathol 2003; 56: 497-506.
10. Turner NC, Reis-Filho JS,. Tackling the diversity of triple-negative breast cancer. Clin Cancer Res 2013; 19: 6380-6388.
11. Foulkes WD, Smith IE, Reis-Filho JS,. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-1948.
12. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
13. Shah SP, Roth A, Goya R, et al,. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486: 395-399.
14. Horlings HM, Weigelt B, Anderson EM, et al,. Genomic profiling of histological special types of breast cancer. Breast Cancer Res Treat 2013; 142: 257-269.
15. Weigelt B, Geyer FC, Reis-Filho JS,. Histological types of breast cancer: how special are they? Mol Oncol 2010; 4: 192-208.
16. Weigelt B, Horlings HM, Kreike B, et al,. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008; 216: 141-150.
17. Weigelt B, Reis-Filho JS,. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nature Rev Clin Oncol 2009; 6: 718-730.
18. Tognon C, Knezevich SR, Huntsman D, et al,. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2: 367-376.
19. Persson M, Andren Y, Mark J, et al,. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 2009; 106: 18740-18744.
20. Wetterskog D, Lopez-Garcia MA, Lambros MB, et al,. Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol 2012; 226: 84-96.
21. Lae M, Freneaux P, Sastre-Garau X, et al,. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod Pathol 2009; 22: 291-298.
22. Wetterskog D, Wilkerson PM, Rodrigues DN, et al,. Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations. Histopathology 2013; 62: 543-550.
23. Ripamonti CB, Colombo M, Mondini P, et al,. First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report. BMC Cancer 2013; 13: 46.
24. Piscuoglio S, Hodi Z, Katabi N, et al,. Are acinic cell carcinomas of the breast and salivary glands distinct diseases? Histopathology 2015; DOI: 10.1111/his.12673.
25. Elston CW, Ellis IO,. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
26. Natrajan R, Wilkerson PM, Marchiò C, et al,. Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J Pathol 2014; 232: 553-565.
27. Geyer FC, Lacroix-Triki M, Colombo PE, et al,. Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. Histopathology 2012; 60: E115-E130.
28. Weinreb I, Piscuoglio S, Martelotto LG, et al,. Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nature Genet 2014; 46: 1166-1169.
29. Cheng DT, Mitchell TN, Zehir A, et al,. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 2015; 17: 251-264.
30. Li H, Durbin R,. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
31. McKenna A, Hanna M, Banks E, et al,. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
32. Cibulskis K, Lawrence MS, Carter SL, et al,. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature Biotechnol 2013; 31: 213-219.
33. Koboldt DC, Zhang Q, Larson DE, et al,. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22: 568-576.
34. Saunders CT, Wong WS, Swamy S, et al,. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 2012; 28: 1811-1817.
35. De Mattos-Arruda L, Weigelt B, Cortes J, et al,. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol 2014; 25: 1729-1735.
36. Sathirapongsasuti JF, Lee H, Horst BA, et al,. Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics 2011; 27: 2648-2654.
37. De Mattos-Arruda L, Bidard FC, Won HH, et al,. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing. Mol Oncol 2014; 8: 150-158.
38. Schwarz JM, Rodelsperger C, Schuelke M, et al,. MutationTaster evaluates disease-causing potential of sequence alterations. Nature Methods 2010; 7: 575-576.
39. Carter H, Chen S, Isik L, et al,. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res 2009; 69: 6660-6667.
40. Martelotto LG, Ng C, De Filippo MR, et al,. Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations. Genome Biol 2014; 15: 484.
41. Kandoth C, McLellan MD, Vandin F, et al,. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502: 333-339.
42. Futreal PA, Coin L, Marshall M, et al,. A census of human cancer genes. Nature Rev Cancer 2004; 4: 177-183.
43. Lawrence MS, Stojanov P, Mermel CH, et al,. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505: 495-501.
44. Carter SL, Cibulskis K, Helman E, et al,. Absolute quantification of somatic DNA alterations in human cancer. Nature Biotechnol 2012; 30: 413-421.
45. Qiao Y, Quinlan AR, Jazaeri AA, et al,. SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization. Genome Biol 2014; 15: 443.
46. Gao J, Aksoy BA, Dogrusoz U, et al,. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.
47. Turner N, Lambros MB, Horlings HM, et al,. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010; 29: 2013-2023.
48. Curtis C, Shah SP, Chin SF, et al,. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.
49. Gonzalez-Angulo AM, Timms KM, Liu S, et al,. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011; 17: 1082-1089.
50. Young SR, Pilarski RT, Donenberg T, et al,. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 2009; 9: 86.
51. Fostira F, Tsitlaidou M, Papadimitriou C, et al,. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat 2012; 134: 353-362.
52. Molyneux G, Geyer FC, Magnay FA, et al,. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010; 7: 403-417.
53. Liu X, Holstege H, van der Gulden H, et al,. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A 2007; 104: 12111-12116.
54. Skálová A, Sima R, Vanecek T, et al,. Acinic cell carcinoma with high-grade transformation: a report of 9 cases with immunohistochemical study and analysis of TP53 and HER-2/neu genes. Am J Surg Pathol 2009; 33: 1137-1145.
55. Tan DS, Marchiõ C, Jones RL, et al,. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008; 111: 27-44.
56. Hammond ME, Hayes DF, Dowsett M, et al,. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
57. Wolff AC, Hammond ME, Hicks DG, et al,. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997-4013.
58. Osako T, Takeuchi K, Horii R, et al,. Secretory carcinoma of the breast and its histopathological mimics: value of markers for differential diagnosis. Histopathology 2013; 63: 509-519.
59. Dowsett M, Nielsen TO, A'Hern R, et al,. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011; 103: 1656-1664.
60. Venkatraman ES, Olshen AB,. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007; 23: 657-663.
61. Mermel CH, Schumacher SE, Hill B, et al,. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011; 12: R41.
62. Li H, Durbin R,. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 2010; 26: 589-595.
63. Landau DA, Carter SL, Stojanov P, et al,. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-726.
64. Fraley C, Raftery AE, Murphy TB, et al,. mclust Version 4 for R: Normal Mixture Modeling for Model-Based Clustering, Classification, and Density Estimation. Technical Report No. 597. Department of Statistics, University of Washington, 2012.
65. Piscuoglio S, Ng CK, Martelotto LG, et al,. Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. Mol Oncol 2014; 8: 1588-1602.